Towards next generation adenosine A2A receptor antagonists

Current Medicinal Chemistry

Volumn 21, Issue 34, 2014, Pages 3918-3935

  Yuan, G ^a   Jones, G B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

A2AR antagonists; Aqueous solubility; Cancer immunotherapy; Molecular modeling; Parkinson's disease; PET imaging; X ray crystallography

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; DOPAMINE 2 RECEPTOR; IMMUNOMODULATING AGENT; THEOPHYLLINE; XANTHINE DERIVATIVE; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; MOLECULAR MODEL; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; X RAY CRYSTALLOGRAPHY;

EID: 84927511762     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140826115123     Document Type: Article

References (126)

1. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53(4), 527-552.
2. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50(3), 413-492.
3. Peterfreund, R. A.; MacCollin, M.; Gusella, J.; Fink, J. S. Characterization and expression of the human A2A adenosine receptor gene. J. Neurochem., 1996, 66(1), 362-368.
4. Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5(3), 247-264.
5. (a) Schwarzschild, M. A.; Agnati, L.; Fuxe, K.; Chen, J. F.; Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci., 2006, 29(11), 647-654.
6. (b) Salamone, J. D. Facing dyskinesia in Parkinson's disease: nondopaminergic approaches. Drugs Fut., 2010, 35(7), 567-573.
7. (c) Fox, S. H. Nondopaminergic treatments for motor control in Parkinson's disease. Drugs, 2013, 73(13), 1405-1415.
8. Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Borioni, A.; Viziano, M.; Dionisotti, S.; Ongini, E. Current developments of A2A adenosine receptor antagonists. Curr. Med. Chem., 1995, 2(3), 707-722.
9. Müller, C. E.; Stein, B. Adenosine receptor antagonists: structure and potential therapeutic applications. Curr. Pharm. Des., 1996, 2, 501-530.
10. Müller, C. E.; Scior, T. Adenosine receptors and their modulators. Pharm. Acta. Helv., 1993, 68(2), 77-111.
11. Jacobson, K. A.; Suzuki, F. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. Drug Dev. Res., 1996, 39(3-4), 289-300.
12. Poulsen, S. A.; Quinn, R. J. Adenosine receptors: New opportunities for the future drugs. Bioorg. Med. Chem., 1998, 6(6), 619-641.
13. Costanzi, S.; Ivanov, A. A.; Tikhonova, I. G.; Jacobson, K. A. Structure and function of G-protein coupled receptors studied using sequence analysis, molecular modeling and receptor engineering: adenosine receptors. Front. Drug Des. Discovery, 2007, 3(1), 63-79.
14. Piirainen, H.; Ashok, Y.; Nanekar, R. T.; Jaakola, V. P. Structural features of adenosine receptors: From crystal to function. Biochim. Biophys. Acta., 2011 1808(5), 1233-44.
15. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322(5905), 1211-1217.
16. (a) Zhukov, A.; Andrews, S. P.; Errey, J. C.; Robertson, N.; Tehan, B.; Mason J. S.; Marshall, F. H.; Weir, M.; Congreve, M. Biophysical mapping of the adenosine A2A receptor. J. Med. Chem., 2011, 54(13), 4312-4323.
17. (b) Yasuda, M.; Harada, H.; Miyazawa, S.; Kobayashi, S.; Harada, K.; Hida, T.; Shibata, H.; Yasuda, N.; Asano, O.; Kotake, Y. Pharmaceutical Composition Promoting Defecation. U. S. Patent 20, 060, 270, 674, October 30, 2006.
18. (c) Rodríguez, D.; Piñeiro, Á.; Gutiérrez-De-Terán, H. Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors. Biochemistry, 2011, 50(19), 4194-4208.
19. Mishra, C. B.; Sharma, D.; Prakash, A.; Kumari, N.; Kumar, N.; Luthra, P. M. Design and synthesis of (4E)-4-(4-substitutedbenzyli deneamino)-3-substituted-2, 3-dihydro-2-thioxothiazole-5-carbonit rile as novel A2A receptor antagonists. Bioorg. Med. Chem., 2013, 21(19), 6077-6083.
20. Dal Ben, D.; Buccioni, M.; Lambertucci, C.; Thomas, A.; Klotz, K.-N.; Federico, S.; Cacciari, B.; Spalluto, G.; Volpini, R. 8-(2-Furyl) adenine derivatives as A2A adenosine receptor ligands. Eur. J. Med. Chem., 2013, 70, 525-535.
21. Bacilieri, M.; Ciancetta, A.; Paoletta, S.; Federico, S.; Cosconati, S.; Cacciari, B.; Taliani, S.; Da, Settimo. F.; Novellino, E.; Klotz, K.-N.; Spalluto, G.; Moro, S. Revisiting a receptor-based pharmacophore hypothesis for human A2A adenosine receptor antagonists. J. Chem. Inf. Model., 2013, 53(7), 1620-1637.
22. Zhang, L.; Liu, T.; Wang, X.; Wang, J.; Li, G.; Li, Y.; Yang, L.; Wang, Y. Insight into the binding mode and the structural fea tures of the pyrimidine derivatives as human A2Aadenosine receptor antagonists. Biosystems, 2014, 115, 13-22.
23. Langmead, C. J.; Andrews, S. P.; Congreve, M.; Errey, J. C.; Hurrell, E.; Marshall, F. H.; Mason, J. S.; Richardson, C. M.; Robertson, N.; Zhukov, A.; Weir, M. Identification of novel adenosine A2A receptor antagonists by virtual screening. J. Med. Chem., 2012, 55(5), 1904-1909.
24. Andrews, S. P.; Mason, J. S.; Hurrell, E.; Congreve, M. Structurebased drug design of chromone antagonists of the adenosine A2A receptor. Med. Chem. Commun., 2014, 5(5), 571-575.
25. Bennett, K. A.; Tehan, B.; Lebon, G.; Tate, C. G.; Weir, M.; Marshall, F. H.; Langmead, C. J. Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. Mol. Pharmacol., 2013, 83(5), 949-58.
26. Andrews, S. P.; Brown, G. A.; Christopher, J. A. Structure-based and fragment-based GPCR drug discovery. Chem. Med. Chem., 2014, 9(2), 256-275.
27. Chern, Y.; King, K.; Lai, H. L.; Lai, H. T. Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem. Biophys. Res. Commun., 1992, 185(1), 304-309.
28. Daly, J. W.; Padgett, W. L.; Shamim, M. T. Analogues of caffeine and theophylline: Effect of the structural alterations on affinity at adenosine receptors. J. Med. Chem., 1986, 29(7), 1305-1308.
29. Shamim, M. T.; Ukena, D.; Padgett, W. L.; Daly, J. W. Effects of 8-phenyl and 8-cycloalkyl substituents on activity of mono-, di- and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J. Med. Chem., 1989, 32(6), 1231-1237.
30. Erickson, R. H.; Hiner, R. N.; Feeney, S. W.; Blake, P. R.; Rzeszotarski, W. J.; Hicks, R. P.; Costello, D. G.; Abreu, M. E. 1, 3, 8-trisubstituted xanthines. Effects of substitution pattern upon adenosine A1/A2 affinity. J. Med. Chem., 1991, 34(4), 1431-1435.
31. Müller, C. E. A2A adenosine receptor antagonists-future drugs for Parkinson's disease? Drugs Fut., 2010, 25(10), 1043-1052.
32. Rivara, S.; Piersanti, G.; Bartoccini, F.; Diamantini, G.; Pala, D.; Riccioni, T.; Stasi, M. A.; Cabri, W.; Borsini, F.; Mor, M.; Tarzia, G.; Minetti, P. Synthesis of (E)-8-(3-chlorostyryl) caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors. J. Med. Chem., 2013, 56(3), 1247-1261.
33. Müller, C. E.; Sandoval-Ramirez, J.; Schobert, U.; Geis, U.; Frobenius, W.; Klotz, K.-N. 8-(sulfostryryl) xanthines: Watersoluble A2A receptor antagonists. Bioorg. Med. Chem., 1998, 6(6), 707-719.
34. Müller, C. E.; Sauer, T.; Maurinsh, Y.; Huertas, R.; Fülle, F.; Klotz, K.-N.; Nagel, J.; Hauber, W. A2A selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand. Drug Dev. Res., 1998, 45(3-4), 190-197.
35. Sauer, R.; Maurinsh, J.; Reith, U.; Fülle, F.; Klotz, K.-N.; Müller, C. E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A2A-selective adenosine receptor antagonists. J. Med. Chem., 2000, 43(3), 440-448.
36. Hauber, W.; Nagel, J.; Sauer, R.; Müller, C. E. Motor effects induced by a blockade of adenosine A2A receptors in the caudateputamen. Neuroreport, 1998, 9(8), 1803-1806.
37. Vollmann, K.; Qurishi, R.; Hockemeyer, J.; Müller, C. E. Synthesis and properties of a new water soluble prodrug of the adenosine A2A receptor antagonist MSX-2. Molecules, 2008, 13(2), 348-359.
38. Santerre, J. L.; Nunes, E. J.; Kovner, R.; Leser, C. E.; Randall, P. A.; Collins-Praino, L. E.; Lopez Cruz, L.; Correa, M.; Baqi, Y.; Müller, C. E.; Salamone, J. D. The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol. Biochem. Behav., 2012, 102(4), 477-487.
39. Shimada, J.; Suzuki, F.; Nonaka, H.; Ishii, A.; Ichikawa, S. (E)-1, 3-dialkyl-7-methyl-8-(3, 4, 5-trimethoxystyryl) xanthines: potent and selective adenosine A2A antagonists. J. Med. Chem., 1992, 35(12), 2342-2345.
40. Le Witt, P. A.; Guttman, M.; Tetrud, J. W.; Tuite, P. J.; Mori, A.; Chaikin, P.; Sussman, N. M. Adenosine A2A receptor antagonist istradefylline (KW6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol., 2008, 63(3), 295-302.
41. Drabczys̈ka, A.; Karcz, T.; Szymas̈ka, E.; Köse, M.; Müller, C. E.; Paskaleva, M.; Karolak-Wojciechowska, J.; Handzlik, J.; Yuzlenko, O.; Kieć-Kononowicz, K. Synthesis, biological activity and molecular modeling studies of tricyclic alkylimidazo-, pyrimido-anddiazepinopurinediones. Purinergic. Signal., 2013, 9(3), 395-414.
42. Hockemeyer, J.; Burbiel, J.; Müller, C. E. Multigram-scale synthesis, stability and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J. Org. Chem., 2004, 69(10), 3308-3318.
43. Cacciari, B.; Pastorin, G.; Spalluto, G. Medicinal chemistry of A2A adenosine receptor antagonists. Curr. Top. Med. Chem., 2003, 3(4), 403-411.
44. Thomas, R.; Lee, J.; Chevalier, V.; Sadler, S.; Selesniemi, K.; Hatfield, S.; Sitkovsky, M.; Ondrechen, M. J.; Jones, G. B. Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies. Bioorg. Med. Chem., 2013, 21(23), 7453-7464.
45. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; Stone, G. A.; Desai, M.; Williams, M. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem., 1988, 31(5), 1014-1020.
46. Baraldi, P. G.; Manfredini, S.; Simoni, D.; Zappaterra, L.; Zocchi, C.; Dionisotti, S.; Ongini, E. Synthesis of new pyrazolo [4, 3-e]-1, 2, 4-triazolo[1, 5-c] pyrimidine and 1, 2, 3-triazolo [1, 5-c] pyrimidine displaying potent and selective activity as A2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett., 1994, 4(21), 2539-2544.
47. Shah, U.; Boyle, C. D.; Chackalamannil, S.; Neustadt, B. R.; Lindo, N.; Greenlee, W. J.; Foster, C.; Arik, L.; Zhai, Y.; Ng, K.; Wang, S.; Monopoli, A.; Lachowicz, J. E. Biaryl and heteroaryl derivatives of SCH58261 as potent and selective adenosine A2A receptor antagonist. Bioorg. Med. Chem. Lett., 2008, 18(14), 4199-4203.
48. Neustadt, B. R.; Hao, J.; Lindo, N.; Greenlee, W. J.; Stamford, A. W.; Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.; Arik, L.; Lachowicz, J.; Ng, K.; Feng, K. I. Potent, selective and orally active adenosine A2A receptor antagonist: arylpiperazine derivatives of pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg. Med. Chem. Lett., 2007, 17(5), 1376-1380.
49. Hodgson, R. A.; Bertorelli, R.; Varty, G. B.; Lachowicz, J. E.; Forlani, A.; Fredduzzi, S.; Cohen-Williams, M. E.; Higgins, G. A.; Impagnatiello, F.; Nicolussi, E.; Parra, L. E.; Foster, C.; Zhai, Y.; Neustadt, B. R.; Stamford, A. W.; Parker, E. M.; Reggiani, A.; Hunter, J. C. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH412348 [7-[2-[4-2, 4-difluorophen-yl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7Hpyrazolo[4, 3-e][1, 2, 4]-triazolo[1, 5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther., 2009, 330(1), 294-303.
50. Silverman, L. S.; Caldwell, J. P.; Greenlee, W. J.; Kiselgof, E.; Matasi, J. J.; Tulshian, D. B.; Arik, L.; Foster, C.; Bertorelli, R.; Monopoli, A.; Ongini, E. 3H-[1, 2, 4]-triazolo[5, 1-i]purin-5-aminederivatives as adenosine A2A antagonists. Bioorg. Med. Chem. Lett., 2007, 17(6), 1659-1662.
51. Shah, U.; Lankin, C. M.; Boyle, C. D.; Chackalamannil, S.; Greenlee, W. J.; Neustadt, B. R.; Cohen-Williams, M. E.; Higgins, G. A.; Ng, K.; Varty, G. B.; Zhang, H.; Lachowicz, J. E. Design, synthesis, and evaluations of fused heterocyclic analogs of SCH58261 as adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(14), 4204-4209.
52. Harris, J. M.; Neustadt, B. R.; Zhang, H.; Lachowicz, J.; Cohen-Williams, M.; Varty, G.; Hao, J.; Stamford, A. W. Potent and selective adenosine A2A receptor antagonists:[1, 2, 4]-triazolo[4, 3-c]pyrimidin-3-ones. Bioorg. Med. Chem., 2011, 21(8), 2497-2501.
53. Mishra, C. B.; Barodia, S. K.; Prakash, A.; Senthil Kumar, J. B.; Luthra, P. M. Novel 8-(furan-2-yl)-3-substitutedthiazolo[5, 4-e]-[1, 2, 4]triazolo[1, 5-c]pyrimidine-2 (3H)-thioderivatives as potential adenosine A2A receptor antagonists. Bioorg. Med. Chem., 2010, 18(7), 2491-2500.
54. Kumari, N.; Mishra, C. B.; Prakash, A.; Kumar, N.; Mongre, R.; Luthra, P. M. 8-(Furan-2-yl)-3-phenethylthiazolo[5, 4-e][1, 2, 4] triazolo[1, 5-c]pyrimidine-2 (3H)-thione as novel, selective and potentadenosine A2A receptor antagonist. Neurosci. Lett., 2014, 558, 203-207.
55. Shook, B. C.; Rassnick, S. Hall, D.; Rupert, K. C.; Heintzelman, G. R.; Hansen, K.; Chakravarty, D.; Bullington, J. L.; Scannevin, R. H.; Magliaro, B.; Westover, L.; Carroll, K.; Lampron, L.; Russell, R.; Branum, S.; Wells, K.; Damon, S.; Youells, S.; Li, X.; Osbourne, M.; Demarest, K.; Tang, Y.; Rhodes, K.; Jackson, P. F. Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists. Bioorg. Med. Chem. Lett., 2010, 20(9), 2864-2867.
56. Caulkett, P. W. R.; Jones, G.; McPartlin, M.; Renshaw, N. D.; Stewart, S. L.; Wright, B. Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1, 2, 4]triazolo[1, 5-a][1, 3, 5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions. J. Chem. Soc., Perkin Trans. 1, 1995, 7, 801-808.
57. Neustadt, B. R.; Liu, H.; Hao, J.; Greenlee, W. J.; Stamford, A. W.; Foster, C.; Arik, L.; Lachowicz, J.; Zhang, H.; Bertorelli, R.; Fredduzzi, S.; Varty, G.; Cohen-Williams, M.; Ng, K. Potent and selective adenosine A2A receptor antagonists: 1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg. Med. Chem. Lett., 2009, 19(3), 967-971.
58. Vu, C. B.; Pan, D.; Peng, B.; Kumaravel, G.; Smits, G.; Jin, X.; Phadke, D.; Engber, T.; Huang, C.; Reilly, J.; Tam, S.; Grant, D.; Hetu, G.; Petter, R. C. Novel diaminoderivatives of [1, 2, 4]triazolo[1, 5-a][1, 3, 5]triazineas potent and selective adenosine A2A receptor antagonists. J. Med. Chem., 2005, 48(6), 2009-2018.
59. Peng, H.; Kumaravel, G.; Yao, G.; Sha, L.; Wang, J.; Van Vlijmen, H.; Bohnert, T.; Huang, C.; Vu, C. B.; Ensinger, C. L.; Chang, H.; Engber, T. M.; Whalley, E. T.; Petter, R. C. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J. Med. Chem., 2004, 47(25), 6218-6229.
60. Yao, G.; Haque, S.; Sha, L.; Kumaravel, G.; Wang, J.; Engber, T. M.; Whalley, E. T.; Conlon, P. R.; Chang, H.; Kiesman, W. F.; Petter, R. C. Synthesis of alkyne derivatives of a novel triazolopyrazineas A2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett., 2005, 15(3), 511-515.
61. Jörg, M.; Shonberg, J.; Mak, F. S.; Millerm N. D.; Yuriev, E.; Scammells, P. J.; Capuano, B. Novel adenosine A2A receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space. Bioorg. Med. Chem. Lett. 2013, 23(11), 3427-3433.
62. Norcross, R. D. Benzoxazole Derivatives and Their Use as Adenosine Receptor Ligands. W. O. Patent 2, 004, 063, 177, July 29, 2004.
63. Norcross, R. Alzheimer's disease; Parkinson's disease; antidepressants. U. S. Patent 20, 050, 065, 151, March 24, 2005.
64. Flohr, A.; Moreau, J. L.; Poli, S. M.; Riemer, C.; Steward, L. Adenosine receptor antagonist; neuroprotectant, antidepressant, anxiolitic, antihypoxic agent; antiischemic and anticonvulsant; Alzheimer's, Parkinson's, Huntington's diseases, schizophrenia, pain, respiration deficits, attention deficit hyper-activity disorder (ADHA), drug addiction. U. S. Patent 20, 050, 261, 289, November 24, 2005.
65. Bioti Therapies: Biotie to regain global rights to tozadenant from UCB. Press Release, March, 21, 2014.
66. Minetti, P.; Tinti, M. O.; Carminati, P.; Castorina, M.; Di Cesare, M. A.; Di Serio, S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; Bartoccini, F.; Tarzia, G. 2-n-Butyl-9-methyl-8-[1, 2, 3]triazol-2-yl-9H-purin-6-ylamine and analogs as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J. Med. Chem., 2005, 48(22), 6887-6896.
67. Cabri, W.; Minetti, P.; Piersanti, G.; Tarsia, G. Oxidated Derivatives of Triazolypurines Useful as Ligands of the Adenosine A2A Receptor and Their Use as Medicaments. W. O. Patent 2, 010, 106, 145, September 23, 2010.
68. Piersanti, G.; Bartoccini, F.; Lucarini, S.; Cabri, W.; Stasi, M. A.; Riccioni, T.; Borsini, F.; Tarzia, G.; Minetti, P. Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1, 2, 3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease. J. Med. Chem., 2013, 56(13), 5456-5463.
69. Pinna, A.; Volpini, R.; Cristalli, G.; Morelli, M. New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur. J. Pharmacol., 2005, 512(2-3), 157-164.
70. Pinna, A.; Tronci, E.; Schintu, N.; Simola, N.; Volpini, R.; Pontis, S.; Cristalli, G.; Morelli, M. A new ethyladenine antagonist of adenosine A2A receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology, 2010, 58(3), 613-623.
71. Yang, M.; Soohoo, D.; Soelaiman, S.; Kalla, R.; Zabiocki, J.; Chu, N.; Leung, K.; Yao, L.; Diamond, I.; Belardinelli, L.; Shryock, J. C. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn-Schmiede-berg's Arch. Pharmacol., 2007, 375(2), 133-144.
72. Gillespie, R. J.; Cliffe, I. A.; Dawson, C. E.; Dourish, C. T.; Gaur, S.; Jordan, A. M.; Knight, A. R.; Lerpiniere, J.; Misra, A.; Pratt, R. M.; Roffey, J.; Stratton, G. C.; Upton, R.; Weiss, S. M.; Williamson, D. S. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3, 4-d]pyrimidines, pyrrolo[2, 3-d]-pyrdimidines and 6-arylpurines. Bioorg. Med. Chem. Lett., 2008, 18(9), 2924-2929.
73. Gillespie, R. J.; Bamford, S. J.; Botting, R.; Comer, M.; Denny, S.; Gaur, S.; Griffin, M.; Jordan, A. M.; Knight, A. R.; Lerpiniere, J.; Leonardi, S.; Lightowler, S.; McAteer, S.; Merrett, A.; Misra, A.; Padfield, A.; Reece, M.; Saadi, M.; Selwood, D. L.; Stratton, G. C.; Surry, D.; Todd, R.; Tong, X.; Ruston, V.; Upton, R.; Weiss, S. M. Antagonist of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluations of 7-aryltriazolo[4, 5-d]pyrimidines. J. Med. Chem., 2009, 52(1), 33-47.
74. Mayer, S.; Schann, S. New Adenosine Receptor Ligands and Uses Thereof. W. O. Patent 2, 010, 084, 425, July 29, 2010.
75. Saku, O.; Saki, M.; Kurosawa, M.; Ikeda, K.; Takizawa, T.; Uesaka, N. Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg. Med. Chem. Lett., 2010, 20(3), 1090-1093.
76. Saku, O.; Saki, M.; Kurokawa, M.; Ikeda, K.; Uchida, S.; Takizawa, T.; Uesaka, N. Synthetic studies on selective adenosine A2Areceptor antagonists. Part II: Synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg. Med. Chem. Lett., 2010, 20(12), 3768-3771.
77. Shook, B. C.; Charavarty, D.; Barbay, J. K.; Wang, A.; Leonard, K.; Alford, V.; Powell, M.; Beauchamp, D. A.; Rassnick, S.; Scannevin, R.; Carroll, K.; Wallace, N.; Crooke, J.; Ault, M.; Lampron, L.; Westover, L.; Rhodes, K.; Jackson, P. F. Aminomethyl substituted thieno[2, 3-d]pyrimidines as adenosine A2A receptor antagonists. Med. Chem. Commun., 2011, 2(10), 950-965.
78. Gütschow, M.; Schlenk, M.; Gäb, J.; Paskaleva, M.; Alnouri, M. W.; Scolari, S.; Iqbal, J.; Müller, C. E. Benzothiazinones: a novel class of adenosine receptor antagonists structurally unrelated to xanthine andadenine derivatives. J. Med. Chem., 2012, 55(7), 3331-41.
79. Stössel, A.; Schlenk, M.; Hinz, S.; Küppers, P.; Heer, J.; Gütschow, M.; Müller, C. E. Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3, 1-benzothiazin-4-ones. J. Med. Chem., 2013, 56(11), 4580-4596.
80. Langmead, C. J.; Andrews, S. P.; Congreve, M.; Errey, J. C.; Hurrell, E.; Marshall, F. H.; Mason, J. S.; Richardson, C. M.; Robertson, N.; Zhukov, A.; Weir, M. Identification of novel adenosine A2A receptor antagonists by virtual screening. J. Med. Chem., 2012, 55(5), 1904-1909.
81. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hollenstein, K.; Hurrell, E.; Langmead, C. J.; Mason, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A.; Weir, M.; Marshall, F. H. Discovery of 1, 2, 4-triazinederivatives as adenosine A2A antagonists using structure based drug design. J. Med. Chem., 2012, 55(5), 1898-1903.
82. Slee, D. H.; Zhang, X.; Moorjani, M.; Lin, E.; Lanier, M. C.; Chen, Y.; Rueter, J. K.; Lechner, S. M.; Markison, S.; Malany, S.; Joswig, T.; Santos, M.; Gross, R. S.; Williams, J. P.; Castro-Palomino, J. C.; Crespo, M. I.; Prat, M.; Gual, S.; Diaz, J.-L.; Wen, J.; O'Brien, Z.; Saunders, J. Identification of novel, water-soluble, 2-amino-Npyrimidine-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J. Med. Chem., 2008, 51(3), 400-406.
83. Slee, D. H.; Chen, Y.; Zhang, X.; Moorjani, M.; Lin, E.; Lanier, M. C.; Lin, E.; Rueter, J. K.; Williams, J. P.; Lechner, S. M.; Markison, S.; Malany, S.; Santos, M.; Gross, R. S.; Jalali, K.; Sai, Y.; Zuo, Z.; Yang, C.; Castro-Palomino, J. C.; Crespo, M. I.; Prat, M.; Gual, S.; Diaz, J.-L.; Saunders, J. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents. J. Med. Chem., 2008, 51(6), 1719-1729.
84. Zhang, X.; Rueter, J. K.; Chen, Y.; Moorjani, M.; Lanier, M. C.; Lin, E.; Gross, R. S.; Tellew, J. E.; Williams, J. P.; Lecher, S. M.; Markison, S.; Joswig, T.; Malany, S.; Santos, M.; Castro-Palomino, J. C.; Crespo, M. I.; Prat, M.; Gual, S.; Diaz, J.-L.; Saunders, J.; Slee, D. H. Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18(6), 1778-1783.
85. Zhang, X.; Tellew, J. E.; Luo, Z.; Moorjani, M.; Lin, E.; Lanier, M. C.; Chen, Y.; Williams, J. P.; Saunders, J.; Lechner, S. M.; Markison, S.; Joswig, T.; Petroski, R.; Piercey, J.; Kargo, W.; Malany, S.; Santos, M.; Gross, R. S.; Wen, J.; Jalali, K.; O'Brien, Z.; Stotz, C. E.; Crespo, M. I.; Diaz, J.-L.; Slee, D. H. Lead optimization of 4-acetylamino-2-(3, 5-dimetylpyrazol-1yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J. Med. Chem., 2008, 51(22), 7099-7110.
86. Lanier, M. C.; Moorjani, M.; Luo, Z.; Chen, Y.; Lin, E.; Tellew, J. E.; Zhang, X.; Williams, J. P.; Gross, R. S.; Lechner, S. M.; Markison, S.; Joswig, T.; Kargo, W.; Piercey, J.; Santos, M.; Malany, S.; Zhao, M.; Petroski, R.; Crespo, M. I.; Diaz, J. L.; Saunders, J.; Wen, J.; O'Brien, Z.; Jalali, K.; Madan, A.; Slee, D. H. N-[6-amino-2-(heteroaryl) pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy. J. Med. Chem., 2009, 52(3), 709-717.
87. Yang, Z.; Li, X.; Ma, H.; Zheng, J.; Zhen, X.; Zhang, X. Replacement of amide with bioisosteres led toa new series of potent adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett., 2014, 24(1), 152-155.
88. Sams, A. G.; Mikkelsen, G. K.; Larsen, M.; Langgard, M.; Howells, M. E.; Schroder, T. J.; Brennum, L. T.; Torup, L.; Jorgensen, E. B.; Bundgaard, C.; Kreilgard, M.; Bang-Andersen, B. Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3, 3-dimethyl-butyrylamino)-3, 5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA2A receptor antagonist. J. Med. Chem., 2011, 54(3), 751-764.
89. Collins, L. E.; Sager, T. N.; Sams, A. G.; Pennarola, A.; Port, R. G.; Shahriari, M.; Salamone, J. D. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol. Biochem. Behav., 2012, 100(3), 498-505.
90. Gillespie, R. J.; Bamford, S. J.; Clay, A.; Gaur, S.; Haymes, T.; Jackson, P. S.; Jordan, A. M.; Klenke, B.; Leonardi, S.; Liu, J.; Mansell, H. L.; Ng, S.; Saadi, M.; Simmonite, H.; Stratton, G. C.; Todd, R. S.; Williamson, D. S.; Yule, I. A. Antagonists of the human A2A receptor. Part 6: Further optimization of pyridmidine-4-carboxamides. Bioorg. Med. Chem. Lett., 2009, 17(18), 6590-6605.
91. Gillespie, R. J.; Bamford, S. J.; Gaur, S.; Jordan, A. M.; Lerpiniere, J.; Mansell, H. L.; Stratton, G. C. Antagonists of the human A2A receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. Bioorg. Med. Chem. Lett., 2009, 19(10), 2664-2667.
92. Mihara, T.; Noda, A.; Arai, H.; Mihara, K.; Iwashita, A.; Murakami, Y.; Matsuya, T.; Miyoshi, S.; Nishimura, S.; Matsuoka, N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. J. Nucl. Med., 2008, 49(7), 1183-1188.
93. Nieto, M. I.; Balo, M. C.; Brea, J.; Caamaño, O.; Cadavid, M. I.; Fernández, F.; Mera, X. G.; López, C.; Rodríguez-Borges, J. E. Synthesis of novel 1-alkyl-8-substituted-3-(3-methoxypropyl) xanthines as putative A (2B) receptor antagonists. Bioorg. Med. Chem., 2009, 17(9), 3426-3432.
94. La Beaume, P.; Dong, M.; Sitkovsky, M.; Jones, E. V.; Thomas, R.; Sadler, S.; Kallmerten, A. E.; Jones, G. B. An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives. Org. Biomol. Chem., 2010, 8(18), 4155-4157.
95. Bandyopadhyay, P.; Agrawal, S. K.; Sathea, M.; Sharmab, P.; Kaushika, M. P. A facile and rapid one-step synthesis of 8-substituted xanthine derivatives via tandem ring closure at room temperature. Tetrahedron, 2012, 68(20), 3822-3827.
96. Jörg, M.; Agostino, M.; Yuriev, E.; Mak, F. S.; Miller, N. D.; White, J. M.; Scammells, P. J.; Capuano, B. Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385. Struct. Chem., 2013, 24(4), 1241-1251.
97. Neustadt, B. R.; Lindo, N. A.; Greenlee, W. J.; Tulshian, D.; Silverman, L. S.; Xia, Y.; Boyle, C. D.; Chackalamannil, S. Adenosine A2a receptor antagonists. W. O. Patent 2, 001, 092, 264, December 6, 2001.
98. Matasi, J. J.; Caldwell, J. P.; Tulshian, D.; Silverman, L. S.; Neustadt, B. R. Adenosine A2a receptor antagonists. W. O. Patent 2, 003, 048, 164, June 12, 2003.
99. Kuo, S. C.; Tran, L. T.; Zhang, P. Process for preparing substituted 5-amino-pyrazolo-[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. W. O. Patent 2, 005, 054, 245, June 16, 2005.
100. Heimbecher, S. K.; Kou, J. H.; Kazakevich, I. Pharmaceutical compositions. U. S. Patent 20, 060, 009, 504, January 12, 2006.
101. Ehud, M.; Michael, M.; Shai, R. Process and intermediates for the preparation of preladenant and related compounds. W. O. Patent 2, 012, 127, 472, September 27, 2012.
102. Parkinson, J. An essay on the shaking palsy. J. Neurosychiatry Clin. Neurosci., 2002, 14(2), 223-236.
103. Jenner, P.; Olanow, C. W. The pathogenesis of cell death in Parkinson's disease. Neurology, 2006, 66(Suppl. 10)), S24-S36.
104. Mercuri, N. B.; Bernardi, G. The "magic" of L-dopa: Why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci., 2005, 26(7), 341-344.
105. Yamamoto, M.; Schapira, A. H. Dopamine agonists in Parkinson's disease. Expert Rev. Neurother., 2008, 8(4), 671-677.
106. Olanow, C. W. MAO-B inhibitors in Parkinson's disease. Adv. Neurol., 1993, 60, 666-671.
107. Gordin, A.; Brooks, D. J. Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. J. Neurol., 2007, 254(4), IV37-IV48.
108. (a) Olanow, C. W.; Stern, M. B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 2009, 72(21, Suppl. 4), S1-S136.
109. (b) Antonini, A.; Clilia, R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf., 2009, 32(6), 475-488.
110. Fink, J. S.; Weaver, D. R.; Rivkees, S. A.; Peterfreund, R. A.; Pollack, A. E.; Adler, E. M.; Reppert, S. M. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol. Brain Res., 1992, 14(3), 186-195.
111. Bara-Jimenez, W.; Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris, M. J.; Mouradian, M. M.; Chase, T. N. Adenosine A2A receptor antagonist treatment of Parkinson's disease. Neurology, 2003, 61(3), 293-296.
112. De Lera Ruiz, M.; Lim, Y. H.; Zheng, J. Adenosine A2A receptor as a drug discovery target. J. Med. Chem., 2014, 57(9), 3623-3650.
113. Kyowa Hakko Kirin Co. Ltd: Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) Press Release, February 28, 2008.
114. ® tablets 20 mg, a novel antiparkinsonian agent. Press Release, March 25, 2013.
115. Merck Press Release, May 23, 2013.
116. Vernalis: Vernalis Announces A2A Receptor Antagonist Programme for Parkinson's Disease Continues with Next Generation Compound. Press Release, July 16, 2010.
117. Deharo, J. C.; Mechulan, A.; Giorgi, R.; Franceschi, F.; Prevot, S.; Peyrouse, E.; Condo, J.; By, Y.; Ruf, J.; Brignole, M.; Guieu, R. Adenosine plasma level and adenosine A2A receptor expression: correlation with laboratory tests in patients with neurally mediated syncope. Heart, 2012, 98(11), 855-9.
118. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79(12A), 2-10.
119. Zuñiga-Ramírez, C.; Micheli, F. Preladenant: an adenosine A2A receptor antagonist for Parkinson's disease. Future Neurol., 2013, 8(6), 639.
120. Pinna, A.; Morelli, M. A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The Case of adenosine A2A receptor antagonists. Neurotox. Res., 2014, 25(4), 392-401.
121. Armentero, M. T.; Pinna, A.; Ferre, S.; Lanciego, J. L.; Müller, C. E.; Franco, R. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther., 2011, 132(3), 280-299.
122. Ohta, A.; Gorelik, E.; Prasad, S. J.; Ronchese, F.; Lukashev, D.; Wong, M. K.; Huang, X.; Caldwell, S.; Liu, K.; Smith, P.; Chen, J. F.; Jackson, E. K.; Apasov, S.; Abrams, S.; Sitkovsky, M. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA., 2006, 103(35), 13132-13137.
123. Gomez, G.; Sitkovsky, M. Differential requirement for A2A and A3 adenosine receptors for the protective effect of inosine in vivo. Blood, 2003, 102(13), 4472-4478.
124. Sitkovsky, M.; Kjaergaard J.; Lukashev, D.; Ohta, A. Hypoxia-Adenosinergic immunosuppression: tumor protection by T regula tory cells and cancerous tissue hypoxia. Clin. Cancer Res., 2008, 14(19), 5947-5952.
125. Ohta, A.; Madasu, M.; Subramanian, M.; Kini, R.; Jones, G.; Chouker, A.; Ohta, A.; Sitkovsky, M. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible. Int. Immuno., 2014, 26(2), 83-91.
126. Wang, X.; Li, Y.; Deuther-Conrad, W.; Xie, F.; Chen, X.; Cui, M. C.; Zhang, X. J.; Zhang, J. M.; Steinbach, J.; Brust, P.; Liu, B. L.; Jia, H. M. Synthesis and biological evaluation of 18F labeled fluro-oligo-ethoxylated 4-benzylpiperazine derivatives for sigma-1 receptor imaging. Bioorg. Med. Chem., 2013, 21(1), 215-222.